Advanced Medical Optics Inc (1168335) SEC Filing 10-Q Quarterly report for the period ending Friday, June 29, 2007

Abbott Medical Optics Inc

CIK: 1168335






Sheree Aronson, Corporate Vice President,

Investor Relations and Corporate Communications

(714) 247-8290



Steve Chesterman, Manager, Corporate


(714) 247-8711




Mark Levin, Manager, Investor Relations

(714) 247-8465






Integration of IntraLase Drove Pro Forma Laser Vision Correction Sales Growth of 17% on Strong Procedure Volume and Unit Placements



Eye Care Business Executed Multipurpose Solution Recall; Preparing for August Market Re-Entry Ahead of Previous Timeline




Tecnis® Monofocal and Refractive Implant Sales Fueled 8% IOL Growth



Company Reaffirms 2007 and 2008 Financial Guidance

(SANTA ANA, CA), August 2, 2007 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE], a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the second quarter of 2007.

The company’s second-quarter 2007 net sales rose 1.7 percent to $261.4 million. The sales increases related to the April 2007 acquisition of IntraLase Corp. and organic growth were offset by lost sales and product returns related to the May 2007 MoisturePlus recall. Foreign currency impacts increased net sales by 1.7 percent.

AMO reported a second-quarter net loss under Generally Accepted Accounting Principles (GAAP) of $166.8 million, or a loss of $2.78 per share, which included the impact of the recall. These results also included the following items, which combined to increase the net loss per share by approximately $1.98:



$85.4 million pre-tax, non-cash in-process research and development (R&D) charge and a $7.7 million pre-tax, non-cash inventory step-up to fair value charge related to the IntraLase acquisition.


- more -

The following information was filed by Abbott Medical Optics Inc on Thursday, August 2, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Abbott Medical Optics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abbott Medical Optics Inc.


Assess how Abbott Medical Optics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abbott Medical Optics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2007 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1168335
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-07-175330
Submitted to the SEC: Wed Aug 08 2007 2:20:51 PM EST
Accepted by the SEC: Wed Aug 08 2007
Period: Friday, June 29, 2007
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink: